Aptamer lifts revenues as licensing strategy gains momentum

Aptamer Group has reported a strong first half performance, with revenues rising 27% as the AIM-listed life sciences business accelerates its shift towards a recurring, licensing-led revenue model.

The York-based developer of next-generation synthetic binders said revenues for the six months to 31 December 2025 reached £0.83m, up from £0.65m a year earlier, giving the board confidence that full-year revenues will materially exceed the prior year.

click here or login below...